Show simple item record

dc.contributor.authorChoudhury, Ananya
dc.contributor.authorWest, Catharine M L
dc.contributor.authorPorta, N
dc.contributor.authorHall, E
dc.contributor.authorDenley, H
dc.contributor.authorHendron, C
dc.contributor.authorLewis, R
dc.contributor.authorHussain, S
dc.contributor.authorHuddart, R
dc.contributor.authorJames, N
dc.date.accessioned2017-03-04T18:52:19Z
dc.date.available2017-03-04T18:52:19Z
dc.date.issued2017-01-26
dc.identifier.citationThe predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). 2017, 116: 649-657 Br J Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid28125821
dc.identifier.doi10.1038/bjc.2017.2
dc.identifier.urihttp://hdl.handle.net/10541/620171
dc.description.abstractSevere chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy. Adding mitomycin C (MMC) and 5-fluorouracil (5-FU) chemotherapy to radiotherapy improved locoregional control (LRC) compared to radiotherapy alone in the BC2001 trial. We hypothesised that tumour necrosis would not predict benefit for the addition of MMC and 5-FU to radiotherapy, but would be prognostic.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleThe predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).en
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester M20 4BXen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractSevere chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy. Adding mitomycin C (MMC) and 5-fluorouracil (5-FU) chemotherapy to radiotherapy improved locoregional control (LRC) compared to radiotherapy alone in the BC2001 trial. We hypothesised that tumour necrosis would not predict benefit for the addition of MMC and 5-FU to radiotherapy, but would be prognostic.


This item appears in the following Collection(s)

Show simple item record